Previous 10 | Next 10 |
2023-05-03 09:05:24 ET Immix Biopharma ( NASDAQ: IMMX ) reported early interim data from a phase 1b/2a trial of IMX-110 in combination with Novartis ( NYSE: NVS ) and BeiGene's ( NASDAQ: BGNE ) tislelizumab to treat patients with advanced metastatic co...
2023-05-03 08:28:28 ET Guardforce AI GFAI -60% raises $8M through equity offering priced at $4.65, shares down 58%. VCI Global Limited ( VCIG ) -50% . Actelis Networks ( ASNS ) -45% . Leju Holdings Limited ( LEJU ) -30% . Minim ( MINM ) ...
100% Tumor Shrinkage at 2-months in advanced metastatic colorectal cancer was demonstrated by IMX-110 + BeiGene / Novartis anti-PD-1 Antibody Tislelizumab combination in the first, lowest dose cohort (two out of two first evaluable patients) in its ongoing phase 1b/2a dose escalation clinical tri...
2023-04-27 12:24:19 ET Gainers: TOP Financial Group Limited ( TOP ) +186% . Evelo Biosciences ( EVLO ) +184% . ContraFect Corporation ( CFRX ) +68% . U Power Limited Ordinary Shares ( UCAR ) +40% . Atomera Incorporated ( ATOM ) +33...
2023-04-27 12:24:19 ET Gainers: TOP Financial Group Limited ( TOP ) +186% . Evelo Biosciences ( EVLO ) +184% . ContraFect Corporation ( CFRX ) +68% . U Power Limited Ordinary Shares ( UCAR ) +40% . Atomera Incorporated ( ATOM ) +33...
2023-04-27 10:01:57 ET Gainers: ContraFect ( CFRX ) +112% . Accuray ( ARAY ) +14% . Mainz Biomed ( MYNZ ) +15% . Mangoceuticals ( MGRX ) +14% . Immix Biopharma ( IMMX ) +9% . Losers: Baudax Bio ( BXRX ) -52% ....
2023-04-27 09:38:46 ET Immix Biopharma's ( NASDAQ: IMMX ) subsidiary Nexcella released positive results from its ongoing Phase 1b/2 NEXICART-1 study on NXC-201, its autologous BCMA-targeted CAR-T cell therapy. to treat relapsed or refractory ( AL ) amyloidosis a...
Multiple Myeloma 92% was the overall response rate produced by NXC-201 in relapsed/refractory multiple myeloma patients treated at the therapeutic dose of 800 million CAR+T cells in its ongoing phase 1b/2a NEXICART-1 clinical trial (NCT04720313) who were not exposed to prior BCMA-targeted t...
LOS ANGELES, April 04, 2023 (GLOBE NEWSWIRE) -- Nexcella Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) today announced that updated NXC-201 clinical data has been selected to be presented at...
LOS ANGELES, March 31, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) today announced that an editorial written by Maria Sjöstrand and Michel Sadelain ...
News, Short Squeeze, Breakout and More Instantly...
LOS ANGELES, CA, July 25, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”) (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and...
Lead site Memorial Sloan Kettering Cancer Center (MSKCC) Timing of milestone in-line with mid-2024 guidance Data from ex-US clinical trial reported at ASGCT 2024 showed a 92% overall response rate LOS ANGELES, July 08, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 4.6% to $128.28 on volume of 215,349,874 shares Zoomcar Holdings Inc. (ZCAR) rose 34.0% to $0.183 on volume of 204,010,215 shares Maxeon Solar Technologies Ltd. (MAXN) fell 3.5% to $0.1736 on volume of 2...